The company must return over 418 million rubles ($5.03 million) to the state for overpricing a unique drug.
Russia's Federal Antimonopoly Service (FAS) has ordered Zambon-Pharma to return more than 418 million rubles ($5.03 million) in illegal profits for setting a monopoly price on the unique drug Fluimucil-Antibiotic IT.
As the sole importer of Fluimucil-Antibiotic IT (active ingredient: thiamphenicol glycinate acetylcysteinate), the company raised the drug’s price by 46% between 2023 and the first quarter of 2025.
The medicine is used to treat infectious and inflammatory respiratory diseases. According to state registry data, it was registered in May 2025 and has no equivalents in Russia. It is not included in the list of essential drugs and is not subject to state price regulation.
FAS found Zambon-Pharma in violation of antitrust laws by setting a monopoly price. The agency noted that the company's profit growth far outpaced production cost increases, while the composition of sellers and buyers and market conditions remained largely unchanged.
The commission ruled that the company must lower the price of the drug to an economically justified level and return 418,824,408 rubles to the state budget. FAS will monitor compliance with its order.
Sources: FAS, Pharmvestnik
